PSMA-TLQ, a metric integrating PSMA tumor volume and PET uptake, was a statistically independent prognosticator of survival in a multivariate analysis and might be a new PET based metric to prognosticate response to radioligand therapies. This evidence concerns the gene FOLH1 and neoplasm.